Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24036211 | 0.91 | KMT2A (0.33) | KMT2ATP53GAACYP4F2CYP4A11 | |
| SCHEMBL2633836 | 0.88 | RORC (0.33) | KMT2ACYP4F2CYP4A11 | |
| SCHEMBL2633916 | 0.86 | TP53 (0.36) | KMT2ATP53GAASMN1; SMN2CYP4F2 | |
| SCHEMBL15237366 | 0.84 | CYP4F2 (0.35) | KMT2ACYP4F2CYP4A11POLB | |
| SCHEMBL24907076 | 0.83 | TP53 (0.34) | KMT2ATP53GAASMN1; SMN2CYP4F2 | |
| SCHEMBL7274953 | 0.83 | CYP4F2 (0.34) | CYP4F2CYP4A11 | |
| SCHEMBL8038035 | 0.81 | GAA (0.39) | KMT2ATP53GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL16875398 | 0.80 | GAA (0.41) | TP53GAASMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL27845134 | 0.80 | CYP4F2 (0.40) | TP53GAASMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL16875400 | 0.80 | GAA (0.41) | TP53GAASMN1; SMN2CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147360-A1 | SSAO INHIBITORS AND USE THEREOF | ECCOGENE INC. | 2021-05-20 | — | — | US | disclosed |
| WO-2021083209-A1 | SSAO INHIBITORS AND USE THEREOF | ECCOGENE (SHANGHAI) CO., LTD. (CN) | 2021-05-06 | — | — | WO | disclosed |
| US-9533995-B2 | Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof | SANOFI (FR) | 2017-01-03 | — | — | US | disclosed |
| US-9533995-B2 | Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof | SANOFI (FR) | 2017-01-03 | — | — | US | disclosed |
| US-9453023-B2 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| US-9453023-B2 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| US-9453023-B2 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| EP-2569280-B1 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI SA (FR) | 2015-02-25 | — | — | EP | disclosed |
| EP-2569280-B1 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI SA (FR) | 2015-02-25 | — | — | EP | disclosed |
| US-20140315923-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-10-23 | — | — | US | disclosed |
| US-20130059863-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-03-07 | — | — | US | disclosed |
| US-20130059874-A1 | SUBSTITUTED N-PHENYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-03-07 | — | — | US | disclosed |
| US-20130059874-A1 | SUBSTITUTED N-PHENYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-03-07 | — | — | US | disclosed |
| US-20130059874-A1 | SUBSTITUTED N-PHENYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-03-07 | — | — | US | disclosed |
| WO-2011143148-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143148-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143150-A1 | SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143150-A1 | SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143163-A1 | SUBSTITUTED N-PHENYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143163-A1 | SUBSTITUTED N-PHENYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315923-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | CHRM2, NR3C2, NPSR1 | KMT2A 732/4885TP53 4472/4885GAA 4306/4885 |
| US-20210147360-A1 | SSAO INHIBITORS AND USE THEREOF | SSB, HAO1, SORD | KMT2A 4745/4885TP53 2312/4885GAA 63/4885 |
| US-20130059863-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | CHRM2, NR3C2, NPSR1 | KMT2A 732/4885TP53 4472/4885GAA 4306/4885 |
| US-20130059874-A1 | SUBSTITUTED N-PHENYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | NR3C2, NPSR1, NPR1 | KMT2A 1088/4885TP53 4351/4885GAA 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.